Journal article
Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan
Case reports in oncology, Vol.15(2), pp.687-693
07/08/2022
DOI: 10.1159/000525351
PMCID: PMC9386408
PMID: 36157703
Abstract
Neutropenic enterocolitis (NE) is a rare form of inflammatory colitis seen in severely neutropenic patients. Patients with NE typically have severe neutropenia (absolute neutrophil count [ANC] <500/mm
3
) in the setting of exposure to cytotoxic chemotherapy. Taxanes have traditionally been associated with NE, but there has been a growing amount of literature, linking a variety of other chemotherapeutic agents. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising a topoisomerase I inhibitor component conjugated to an antibody targeting human trophoblast cell-surface antigen 2 (Trop-2). SG is approved for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) and urothelial cancer. We report a case of NE in a patient with mTNBC receiving SG and its successful management. Prompt diagnosis and management of NE in such patients can be potentially lifesaving.
Details
- Title: Subtitle
- Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan
- Creators
- Adam Ethan Prescott - University of Iowa Hospitals and ClinicsAditya Ravindra - University of Iowa Hospitals and ClinicsAsad Javed - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Case reports in oncology, Vol.15(2), pp.687-693
- DOI
- 10.1159/000525351
- PMID
- 36157703
- PMCID
- PMC9386408
- NLM abbreviation
- Case Rep Oncol
- ISSN
- 1662-6575
- eISSN
- 1662-6575
- Publisher
- S. Karger AG
- Language
- English
- Date published
- 07/08/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362306102771
Metrics
8 Record Views